CN108779119B - 嘧啶及其变体、及其用途 - Google Patents
嘧啶及其变体、及其用途 Download PDFInfo
- Publication number
- CN108779119B CN108779119B CN201780019534.0A CN201780019534A CN108779119B CN 108779119 B CN108779119 B CN 108779119B CN 201780019534 A CN201780019534 A CN 201780019534A CN 108779119 B CN108779119 B CN 108779119B
- Authority
- CN
- China
- Prior art keywords
- group
- equiv
- compound
- mixture
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313334P | 2016-03-25 | 2016-03-25 | |
| US62/313,334 | 2016-03-25 | ||
| PCT/US2017/023126 WO2017165255A1 (en) | 2016-03-25 | 2017-03-20 | Pyrimidines and variants thereof, and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108779119A CN108779119A (zh) | 2018-11-09 |
| CN108779119B true CN108779119B (zh) | 2022-02-08 |
Family
ID=59900805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780019534.0A Active CN108779119B (zh) | 2016-03-25 | 2017-03-20 | 嘧啶及其变体、及其用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10662162B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3433258B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6902045B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102377805B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108779119B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017237929B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3018180C (cg-RX-API-DMAC7.html) |
| MA (1) | MA44489A (cg-RX-API-DMAC7.html) |
| MX (1) | MX384368B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2760733C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017165255A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10822311B2 (en) | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| KR102377805B1 (ko) | 2016-03-25 | 2022-03-22 | 애퍼런트 파마슈티컬스 인크. | 피리미딘 및 그의 변이체, 및 그의 용도 |
| AU2017381739B2 (en) | 2016-12-19 | 2020-06-11 | Novartis Ag | New picolinic acid derivatives and their use as intermediates |
| US10676444B2 (en) * | 2016-12-20 | 2020-06-09 | Afferent Pharmaceuticals, Inc. | Crystalline salts and polymorphs of a P2X3 antagonist |
| US11414444B2 (en) | 2017-11-01 | 2022-08-16 | Beijing Tide Pharmaceutical Co., Ltd. | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof |
| CN107778255B (zh) * | 2017-11-16 | 2019-10-25 | 山东大学 | 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
| KR20220008286A (ko) * | 2019-04-30 | 2022-01-20 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법 |
| WO2020221275A1 (zh) * | 2019-04-30 | 2020-11-05 | 北京泰德制药股份有限公司 | 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途 |
| US20220211703A1 (en) * | 2019-04-30 | 2022-07-07 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
| EP3981765A4 (en) * | 2019-06-06 | 2023-05-31 | Beijing Tide Pharmaceutical Co., Ltd. | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR USE |
| CN120058573B (zh) * | 2025-04-29 | 2025-12-23 | 潍坊学院 | 一种1-三溴甲基磺酰基萘及其衍生物的合成方法 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| WO2000059893A1 (en) * | 1999-04-06 | 2000-10-12 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
| WO2005095359A1 (en) * | 2004-03-05 | 2005-10-13 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| WO2007025901A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007025925A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007025899A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007025900A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p3x2/3 modulators |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| WO2008104472A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof |
| WO2017160569A1 (en) * | 2016-03-14 | 2017-09-21 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1345926B1 (en) | 2000-12-21 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP2079713B1 (en) * | 2006-10-04 | 2014-04-16 | F. Hoffmann-La Roche AG | Process for synthesis of phenoxy diaminopyrimidine derivatives |
| AU2008319735A1 (en) * | 2007-10-31 | 2009-05-07 | Nissan Chemical Industries, Ltd. | Pyridazinone derivatives and use thereof as P2X7 receptor inhibitors |
| GB2471713A (en) | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| NZ716977A (en) * | 2013-08-23 | 2017-09-29 | Afferent Pharmaceuticals Inc | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases |
| EP3981406A1 (en) * | 2014-07-03 | 2022-04-13 | Afferent Pharmaceuticals Inc. | Methods and compositions for treating diseases and conditions |
| KR102377805B1 (ko) * | 2016-03-25 | 2022-03-22 | 애퍼런트 파마슈티컬스 인크. | 피리미딘 및 그의 변이체, 및 그의 용도 |
-
2017
- 2017-03-20 KR KR1020187029805A patent/KR102377805B1/ko active Active
- 2017-03-20 RU RU2018137032A patent/RU2760733C2/ru active
- 2017-03-20 CN CN201780019534.0A patent/CN108779119B/zh active Active
- 2017-03-20 AU AU2017237929A patent/AU2017237929B2/en active Active
- 2017-03-20 EP EP17770880.7A patent/EP3433258B1/en active Active
- 2017-03-20 US US16/080,840 patent/US10662162B2/en active Active
- 2017-03-20 MA MA044489A patent/MA44489A/fr unknown
- 2017-03-20 WO PCT/US2017/023126 patent/WO2017165255A1/en not_active Ceased
- 2017-03-20 MX MX2018011622A patent/MX384368B/es unknown
- 2017-03-20 CA CA3018180A patent/CA3018180C/en active Active
- 2017-03-20 JP JP2018549444A patent/JP6902045B2/ja active Active
-
2020
- 2020-04-13 US US16/846,452 patent/US11230532B2/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| WO2000059893A1 (en) * | 1999-04-06 | 2000-10-12 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
| WO2005095359A1 (en) * | 2004-03-05 | 2005-10-13 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| WO2007025901A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007025925A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007025899A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007025900A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p3x2/3 modulators |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| WO2008104472A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof |
| WO2017160569A1 (en) * | 2016-03-14 | 2017-09-21 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| CN108834412A (zh) * | 2016-03-14 | 2018-11-16 | 传入制药公司 | 嘧啶及其变体、及其用途 |
Non-Patent Citations (5)
| Title |
|---|
| （5-Arylthiopyrimidines. I. 2,4-Diamino Derivatives;ELVIRA A. FALCO et al.;《Journal of Organic Chemistry》;19610430;第1143-1146页 * |
| 2 , 4-二氨基-5-取代苯胺基嘧啶类化合物的合成及抗菌活性;赵维璋等;《药学学报》;19871231;第541-544页 * |
| Identification and SAR of novel diaminopyrimidines. Part 1: The discoveryof RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain;David S. Carter et al.;《Bioorganic & Medicinal Chemistry Letters》;20090207;第1628-1631页 * |
| Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain;Alam Jahangir et al.;《Bioorganic & Medicinal Chemistry Letters》;20090204;1632-1635页 * |
| REGISTRY[online];Colimbus,Ohio,US;《REGISTRY》;19841116;90767-71-8 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2760733C2 (ru) | 2021-11-30 |
| MA44489A (fr) | 2019-01-30 |
| US20200239421A1 (en) | 2020-07-30 |
| MX2018011622A (es) | 2019-03-28 |
| US10662162B2 (en) | 2020-05-26 |
| US20190055202A1 (en) | 2019-02-21 |
| MX384368B (es) | 2025-03-14 |
| CA3018180C (en) | 2024-02-20 |
| EP3433258B1 (en) | 2023-07-19 |
| AU2017237929B2 (en) | 2021-04-15 |
| JP6902045B2 (ja) | 2021-07-14 |
| AU2017237929A1 (en) | 2018-09-13 |
| KR102377805B1 (ko) | 2022-03-22 |
| JP2019510025A (ja) | 2019-04-11 |
| EP3433258A4 (en) | 2019-10-30 |
| RU2018137032A3 (cg-RX-API-DMAC7.html) | 2020-05-22 |
| EP3433258A1 (en) | 2019-01-30 |
| WO2017165255A1 (en) | 2017-09-28 |
| RU2018137032A (ru) | 2020-04-27 |
| CA3018180A1 (en) | 2017-09-28 |
| KR20180128015A (ko) | 2018-11-30 |
| BR112018069105A2 (pt) | 2019-01-29 |
| US11230532B2 (en) | 2022-01-25 |
| CN108779119A (zh) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108779119B (zh) | 嘧啶及其变体、及其用途 | |
| CN108834412B (zh) | 嘧啶及其变体、及其用途 | |
| TWI577677B (zh) | 作爲ｔｔｘ－ｓ阻斷劑之吡咯並吡啶酮衍生物 | |
| WO2022170802A1 (zh) | 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途 | |
| WO2021227906A1 (zh) | 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 | |
| KR20150128722A (ko) | 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드 | |
| CN106536503A (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
| CN114423758A (zh) | 抗细菌化合物 | |
| HK1210178A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
| CN104812755B (zh) | 作为ttx‑s阻断剂的吡唑并吡啶衍生物 | |
| WO2022170947A1 (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 | |
| TW200815425A (en) | 2,5-disubstituted piperidines | |
| JP7634083B2 (ja) | 新規なピラゾール誘導体 | |
| CN109563033B (zh) | 脂族脯氨酰胺衍生物 | |
| CN106749203B (zh) | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 | |
| CN109206360B (zh) | 咔唑酰胺类衍生物或其盐及其制备方法和用途 | |
| CN114685453A (zh) | 杂环脯氨酰胺衍生物 | |
| CN112759541B (zh) | 类吲哚衍生物及其用途 | |
| BR112018069105B1 (pt) | Composto de pirimidina, composição e uso do mesmo | |
| WO2025209562A1 (zh) | 作为Nav1.8抑制剂的四氢呋喃吡啶酮类化合物 | |
| HK40048952A (en) | Heterocyclic compound, intermediate, preparation method therefor and application thereof | |
| HK40061204B (zh) | 吡嗪类衍生物及其在抑制shp2中的应用 | |
| TW201506011A (zh) | 氮雜環衍生物及其在藥物中的應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: new jersey Patentee after: AFFERENT PHARMACEUTICALS Inc. Address before: California, USA Patentee before: AFFERENT PHARMACEUTICALS Inc. |